연구성과로 돌아가기
2020 연구성과별 연구자 정보 (1515 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacological Treatment of Epilepsy in Elderly Patients | Kim, Daeyoung | Kim, D | 10 | Chungnam Natl Univ, Chungnam Natl Univ Hosp, Sch Med, Dept Neurol, Daejeon, South Korea | 0000-0001-9056-0017 | Kim, Daeyoung | jonggeun.seo@gmail.com;neurocho@gmail.com; | |||
| Phase developments in Pb(Zn[Ta,Nb,W])O3-PbTiO3 ternary ceramic compositions | Lee, Bong-Ho | Lee, BH | 1 | Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu 41566, South Korea | nkkim@knu.ac.kr; | |||||
| Phase developments in Pb(Zn[Ta,Nb,W])O3-PbTiO3 ternary ceramic compositions | Lee, Bong-Ho | Lee, BH | 1 | Daegu Gyeongbuk Inst Sci & Technol, Ctr Core Res Facil, Daegu 42988, South Korea | nkkim@knu.ac.kr; | |||||
| Phase developments in Pb(Zn[Ta,Nb,W])O3-PbTiO3 ternary ceramic compositions | Kim, Nam-Kyoung | Kim, NK | 2 | 교신저자 | Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu 41566, South Korea | nkkim@knu.ac.kr; | ||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Kim, S-B. | Kim, SB | 1 | Asan Med Ctr, Dept Oncol, Seoul, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Keam, B. | Keam, B | 2 | Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Shin, S. | Shin, S | 3 | Kosin Univ Gospel Hosp, Dept Oncol Internal Med, Busan, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Chae, Y. S. | Chae, YS | 4 | Kyungpook Natl Univ, Chilgok Hosp, Dept Hematol Oncol, Daegu, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Seo, S. | Seo, S | 5 | Asan Med Ctr, Dept Oncol, Seoul, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Park, K. | Park, K | 6 | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea | ABD-5852-2021 | Park, Keunchil | ||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Kim, T. M. | Kim, TM | 7 | Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Park, L. C. | Park, LC | 8 | Kosin Univ Gospel Hosp, Dept Oncol Internal Med, Busan, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Hong, S-B. | Hong, SB | 9 | ISU Abxis Co Ltd, Drug Dev, Seongnam, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Lim, E. | Lim, E | 10 | ISU Abxis Co Ltd, Clin Trial Team, Seongnam, South Korea | ||||||
| Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Lee, S. | Lee, S | 11 | ISU Abxis Co Ltd, Clin Trial Team, Seongnam, South Korea |
페이지 이동: